INTRODUCTIONDuring the last three decades, somatostatin has been implicated as a mediator to decrease diarrhoea, because it decreases gastrointestinal motility and intestinal¯uid and electrolyte transport. It was initially discovered in 1968 by accident during studies looking for a growth hormone releasing factor in the rat pituitary, 1 and was subsequently isolated. 2 Because of its short half-life and tachyphylaxis, biochemical manipulation of somatostatin was attempted to produce products with a longer half-life and improved pharmacological properties.3 The best known and most widely used of these is octreotide.Both somatostatin and octreotide exert their biological effects by interacting with ®ve subtypes of receptors (SRs), each produced as a product from different chromosomes.4 While somatostatin is non-selective, octreotide interacts mainly with SR2 and SR5 and less so with SR3. The interaction of somatostatin or octreotide results in the inactivation of adenylate cyclase or the inhibition of Ca 2+ in¯ux and K + ef¯ux
SUMMARYBackground: Somatostatin and octreotide have multiple effects which make them ideal for treating diarrhoea of different aetiologies. Their use in a variety of conditions with refractory diarrhoea, however, is based on a limited number of studies. Aim: We undertook a systematic review of the available English literature to maximize an evidence-based approach to the treatment of refractory diarrhoea. We tested the hypothesis that ef®cacy is independent of aetiology.Methods and results: A Medline and individual article search from 1965 to 2000 was undertaken on the use of somatostatin and octreotide in diarrrhoea. All reports containing at least ®ve subjects were included. The percentage response in case series and randomized controlled trials was compared, and a meta-analysis of